

Sartorius, Immunochina to advance immunotherapy development

04 December 2018 | News

Immunochina will gain preferred access to SSB's bioprocess technology platform for development, scale-up and production.



Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals, has announced that both parties have entered into a collaboration. Under the terms of the relationship, Immunochina will gain preferred access to SSB's bioprocess technology platform for development, scale-up and production, new cellular immunotherapy production equipment and related commercial-scale manufacturing expertise, while Immunochina will provide technical feedback to SSB.

Founded in 2015, Beijing-based Immunochina is a clinical stage biotechnology company developing best-in-class chimeric antigen receptor T-cell (CAR-T) therapies and a lentiviral vector manufacturing platform. The company's lead programs target CD19 in B-Cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin's Lymphoma, with several other drug candidates targeting liquid and solid tumors currently in development.